Phlexglobal Launches Research Nurse Bank
Phlexglobal
, has broadened its personnel provision with the launch of a new Research Nurse Bank.
Following client requests, the Research Nurse Bank has been opened to supply skilled nursing staff on a temporary basis to both commercial and NHS clients. With experience of providing clinical research support at the client’s site, the nurses will be available for all phases of clinical trials.
The new initiative is an extension to Phlexglobal’s Task Force, which supplies experienced clinical research personnel, including CRAs, CTAs, QA personnel, research governance assistants/managers and document managers for interim and short term projects.
To compliment the new Task Force extension, Phlexglobal’s training division has added a new research nurse training program to its recently launched training curriculum, which specialzses in tuition for nurses wishing to move into the clinical research field (Essential Skills for Clinical Researchers: Research Nurse), as well as ongoing development for experienced nurses (Advanced Skills for Research Nurses).
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
